Insulin glargine metabolite 21A‐Gly‐human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study

@article{Danne2015InsulinGM,
  title={Insulin glargine metabolite 21A‐Gly‐human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study},
  author={Thomas Danne and Reinhard H. A. Becker and Lin Ping and Areti Philotheou},
  journal={Pediatric Diabetes},
  year={2015},
  volume={16}
}
Insulin glargine metabolite 21A‐Gly‐human insulin (M1) is the principal component circulating in plasma of adults with type 1 diabetes. The objective of this study was to confirm this finding in young children and to rule out accumulation of parent insulin glargine. 
View on Wiley
auf-der-bult.de
7 Citations
Background Citations
2
Methods Citations
1

7 Citations

Citation Type

Citation Type

Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.
ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes
Refined recommendations on intensive regimens for differential substitution of basal and prandial insulin. Review of the role of new insulin analogs, biosimilars and devices for insulin therapy in…
New Insulins, Biosimilars, and Insulin Therapy.
TLDR
A strategy for the chemical modification of insulin intended to promote both long-lasting and glucose-responsive activity through the incorporation of an aliphatic domain to facilitate hydrophobic interactions, as well as a phenylboronic acid for glucose sensing is demonstrated.
New Insulins, Biosimilars, and Insulin Therapy.
TLDR
A strategy for the chemical modification of insulin intended to promote both long-lasting and glucose-responsive activity through the incorporation of an aliphatic domain to facilitate hydrophobic interactions, as well as a phenylboronic acid for glucose sensing is demonstrated.
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
TLDR
Improved PK/PD properties of newer longer-acting basal insulins may translate into clinical benefits for patients with type 1 and type 2 diabetes, such as more consistent insulin levels in the blood over 24 hours, lower intra-patient variability, a reduced risk of nocturnal hypoglycemia, and more flexibility in dosing time.
Insulin glargine and its two active metabolites: A sensitive (16pM) and robust simultaneous hybrid assay coupling immunoaffinity purification with LC-MS/MS to support biosimilar clinical studies.
  • Yang Xu, Li Sun, +9 authors E. Woolf
  • Biology
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
  • 2017
Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different
TLDR
Evaluating the differences in basal insulin preparations based on their differential mechanisms of protraction, and the resulting clinical action profiles so healthcare providers and payers can make educated and well-informed decisions when determining which treatment regimen best meets the needs of each individual patient is evaluated.

References

SHOWING 1-10 OF 21 REFERENCES
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
TLDR
Metabolites were quantified using immunoaffinity enrichment and liquid chromatography tandem mass spectrometry (LC‐MS/MS) and M1 was confirmed as the principal active moiety circulating in blood, the principal moiety responsible for metabolic effects, and subsequently into M2 in people with type 1 diabetes.
Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
TLDR
After subcutaneous injection ofglargine in male subjects with type 1 diabetes, exposure to glargine is marginal, if any, even at supratherapeutic doses.
Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study
TLDR
Lower HbA1c after 1 year, in children with type 1 diabetes treated with insulin glargine vs. NPH insulin from diagnosis: a retrospective study.
In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
TLDR
The binding of insulin glargine and its metabolites M1 and M2 to the IR were similar and correlated well with their corresponding autophosphorylation and metabolic activities in vitro, and this findings strongly support the idea that insulinglargine metabolites contribute with the same potency to blood glucose control but lead to significantly reduced growth-promoting activity.
Biotransformation of insulin glargine after subcutaneous injection in healthy subjects
TLDR
During treatment with a subcutaneous injection of insulin glargine, metabolic degradation is likely to be initiated at the injection site and continued within the circulatory system.
Flexible Insulin Therapy With Glargine Insulin Improved Glycemic Control and Reduced Severe Hypoglycemia Among Preschool-Aged Children With Type 1 Diabetes Mellitus
TLDR
The findings suggest that FMDI regimens may be a feasible therapeutic alternative to MDI treatment for preschool-aged children with type 1 DM, although excess body weight status appeared to preclude a desirable therapeutic response in this group of patients.
A randomized trial comparing the rate of hypoglycemia—assessed using continuous glucose monitoring—in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study)
Avoidance of hypoglycemia is a key consideration in treating young children with type 1 diabetes (T1DM).
Intravenous infusion of diarginylinsulin, an insulin analogue: effects on glucose turnover and lipid levels in insulin-treated type II diabetic patients.
Does Insulin Glargine Increase the Risk of Cancer ComparedWith Other Basal Insulins? A French nationwide cohort study based on national administrative databases
TLDR
Cox proportional hazards models with age as timescale were used to calculate multivariate-adjusted hazard ratios for associations between type of basal insulin and risk of overall cancer, breast cancer, and seven other cancer sites.
Basal insulin and cardiovascular and other outcomes in dysglycemia.
TLDR
Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight and had a neutral effect on cardiovascular outcomes and cancers.
...
1
2
3
...